Digestion

 

Drug Therapy for Non-Variceal Upper Gastrointestinal Bleeding

Assessment of Options

Jenkins S.A.

Author affiliations

Academic Department of Surgery, Morriston Hospital, Swansea, UK

Keywords: SomatostatinOctreotideNon-variceal upper gastrointestinal bleedingPeptic ulcersVasoactive drugs

Related Articles for ""
Digestion 1999;60(suppl 3):39–49
https://doi.org/10.1159/000051488

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: November 17, 1999
Issue release date: November 1999

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG


First-Page Preview
Abstract of Paper


Related Articles:

References

  1. Longstreth GF: Epidemiology of hospitalisation for acute upper gastrointestinal hemorrhage: A population-based study. Am J Gastroenterol 1995;90:206–210.
    External Resources
  2. Pundzius J: Clinical and endoscopic signs for the prediction of recurrent bleeding from gastroduodenal ulcers. Eur J Surg 1994;160:689–692.
    External Resources
  3. Choudari CP, Rajgopal C, Elton RA, Palmer KR: Failures of endoscopic therapy for bleeding peptic ulcer: An analysis of risk factors. Am J Gastroenterol 1994;89:1968–1972.
    External Resources
  4. Hsu P, Lin XZ, Chan SH, et al: Bleeding peptic ulcer-risk factors for rebleeding and sequential changes in endoscopic findings. Gut 1994;35:746–749.
    External Resources
  5. Park KG, Steele RJ, Mollison J, Crofts TJ: Prediction of recurrent bleeding after endoscopic haemostasis in non-variceal upper gastrointestinal haemorrhage. Br J Surg 1994;81:1465–1468.
    External Resources
  6. Jaramillo J, Galvez C, Carmona C, Montero JL, Mino G: Prediction of further haemorrhage in bleeding peptic ulcer. Am J Gastroenterol 1994;89:2135–2138.
    External Resources
  7. Qvist P, Arnessen KE, Jacobson CD, Rosseland AR: Endoscopic treatment and restrictive surgical policy in the treatment of peptic ulcer bleeding: Five years’ experience in a central hospital. Scand J Gastroenterol 1994;29:569–576.
    External Resources
  8. Villanueva C, Balanzo J, Espinos JC, et al: Prediction of therapeutic failure in patients with bleeding peptic ulcers treated with endoscopic injection. Dig Dis Sci 1993;38:2062–2070.
    External Resources
  9. Lin HJ, Perng CL, Lee PY, Lee CH, Lee SD: Clinical causes and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: A prospective study. Gut 1994;35:389–393.
  10. Heier SK, Gronowits SD, Willner IR, et al: The APACHE III prognostic system: Predicting adverse outcome after heater probe therapy. Gastroenterology 1995;108:A111.
  11. Sambresqui A, Zylberman M, Foncuberta C, et al: Somatostatin for the treatment of upper gastrointestinal bleeding (UGIB) in patients undergoing autologous bone marrow transplantation (ABMT). Bone Marrow Transplant 1995;16:323–326.
  12. Hall M: An A to Z of British medicines research. An occasional publication of the Association of British Pharmaceutical Industry, 1995.
  13. Morgan AG, Clamp SE: OMGE international gastrointestinal bleeding survey, 1978–1986. Scand J Gastroenterol 1988;(suppl)144:51–58.
  14. Rockall TA, Logan RFA, Devlin HB, Northfield TC: Incidence of and mortality from acute upper gastrointestinal haemorrhage in the UK. BMJ 1995;311:222–226.
    External Resources
  15. Peterson WL, Barnett CC, Smith HJ, Allen MH, Corbett DB: Routine early endoscopy in upper gastrointestinal tract bleeding: A randomised controlled trial. N Engl J Med 1981;304:925–929.
    External Resources
  16. Rofe SM, Duggan JM, Smith ER, Thursby GJ: Conservative treatment of gastrointestinal haemorrhage. Gut 1985;26:481–484.
    External Resources
  17. Madden MV, Griffith GH: Management of upper gastrointestinal bleeding in a district general hospital. J R Coll Phys Lond 1986;20:212–215.
    External Resources
  18. Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D: Endoscopic haemostasis – an effective therapy for bleeding ulcers. JAMA 1990;264:494–499.
    External Resources
  19. Jones PF, Johnston SJ, McCewan AB, Kyle J, Needham CD: Further haemorrhage after admission to hospital for gastrointestinal haemorrhage. Br Med J 1973;iii:600–604.
  20. Soll AH: Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters Committee of the American College of Gastroenterology. JAMA 1996;275:622–629.
    External Resources
  21. Jensen DM: The bleeding ulcer: Stigmata, needles, probes and antibiotics? ASGE Post-Grad Course 1996:3–12.
  22. Swain P: What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? Endoscopy 1995;27:321–328.
    External Resources
  23. Jensen DM, Cheng S, Kouacs TO, et al: A controlled study of ranitidine for the prevention of recurrent haemorrhage from duodenal ulcer. N Engl J Med 1994;300:382–386.
    External Resources
  24. Van der Mierop F, Fleischer DE: Endoscopic hemostasis in nonvariceal bleeding: An overview. Endoscopy 1996;28:321–328.
  25. Brullet E, Calvet X, Campo R, Rue M, Catot L, Donoso L: Factors predicting failure of endoscopic injection therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996a;43:111–116.
  26. Brullet E, Campo R, Calvet X: Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut 1996;32:155–158.
  27. Clason AE, MacLeod DAD, Elton RA: Clinical factors in the prediction of further haemorrhage or mortality in acute upper gastrointestinal bleeding. Br J Surg 1986;93:985–987.
  28. Rockall TA, Logan RFA, Devlin HB, Northfield TC, and tscamotNAoAUGH: Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316–321.
    External Resources
  29. Laine L: Medical progress: Bleeding peptic ulcer. N Engl J Med 1994;331:717–727.
    External Resources
  30. Steffes CP, Sugawa C: Endoscopic management of nonvariceal gastrointestinal bleeding. World J Surg 1992;16:1025–1033.
    External Resources
  31. Konturek SJ, Kwiechien H, Thulin L, Bielanski W, Oleksy T, Schally AV: Effect of somatostatin-14 and somatostatin-28 on plasma hormonal and gastric secretory responses to cephalic and gastrointestinal stimuli in man. Scand J Gastoenterol 1985;20:31–38.
  32. Creutzfedlt W, Arnold R: Somatostatin and the stomach: Exocrine and endocine aspects. Metabolism 1978;27:1309–1315.
    External Resources
  33. Mogard MH, Maxwell V, Kovacs T, et al: Somatostatin inhibits gastric acid secretion after gastric mucosal prostaglandin synthesis inhibition by indomethacin in man. Gut 1985;26:1189–1191.
    External Resources
  34. Sandvic A, Waldrum H: The effects of somatostatin on baseline and stimulated acid secretion and vascular histamine release from the totally isolated vascularly perfused rat stomach. Regul Pept 1988;20:233–239.
    External Resources
  35. Gomez-Pan A, Reel J, Albinus M, Shaw B, Hall R: Direct inhibition of gastric acid and pepsin secretion by growth hormone in cats. Lancet 1974;i:888–890.
  36. Hirschowitz BJPET: Somatostatin effects on gastric electrolytes and pepsin in dogs with various secretory stimuli. J Pharmacol Exp Ther 1987;243:501–506.
    External Resources
  37. Li MKK, Sung JJY, Woo KS, et al: Somatostatin reduces gastric mucosal blood flow in patients with portal hypertensive gastropathy: A randomised, double-blind crossover study. Dig Dis Sci 1996;41:2440–2446.
    External Resources
  38. Panés J, Piqué JM, Bordas JM, et al: Effects of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994;20:336–341.
    External Resources
  39. Krejs GJ: Physiological role of somatostatin in the digestive tract: Gastric acid secretion, intestinal absorption and motility. Scand J Gastroenterol 1986;2(suppl 119):47–53.
  40. Arnold R, Lankisch PG: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 1980;9:733–753.
    External Resources
  41. Peeters TL, Janssen J, Vantrappen C: Somatostatin and the intergastric migrating model complex in man. Regul Pept 1983;5:209–217.
    External Resources
  42. Johansson C, Efendic S, Wisén O, Uvnäs-Wallensten K, Luft R: Effects of short-term somatostatin infusion on gastric and intestinal propulsion in humans. Scand J Gastroenterol 1978;13:481–482.
    External Resources
  43. Johansson C, Wisén O, Efendic S, Uvnäs-Wallensten K: Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 1981;22:126–137.
    External Resources
  44. Johansson C, Ally A: Stimulation of gastric mucus output by somatostatin in man. Eur J Clin Invest 1982;12:37–39.
    External Resources
  45. Green FWJ, Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor to prolonged gastro-duodenal mucosal haemorrhage. Gastroenterology 1978;74:38–43.
    External Resources
  46. Park J, Chiba T, Yamada T: Mechanisms for direct inhibition of canine gastric parietal cells by somatostatin. J Biol Chem 1987;262:14190–14196.
    External Resources
  47. Reyl F, Silve C, Lewin MJM: Somatostatin receptors on isolated gastric cells; in Roselin G, Fromageot P, Bonfils S (eds): Hormone Receptors in Digestion and Nutrition. Amsterdam, Elsevier/North-Holland, 1999, pp 391–400.
  48. Giraud AS, Soll AH, Cuttitta F, Walsh JH: Bombesin stimulation of gastrin release from canine gastrin cells in primary culture. Am J Physiol 1987;252:G413–G420.
    External Resources
  49. Etherington DJ, Taylor WH: Nomenclature of pepsins. Nature 1967;216:279–280.
    External Resources
  50. Taylor WH: Pepsin in patients with peptic ulcer disease. Nature 1976;277:760–767.
  51. Walker V, Taylor WH: Pepsin I secretion in chronic peptic ulceration. Gut 1980;21:776–781.
  52. Pearson JP, Ward R, Allen A, Roberts NB, Taylor WH: Mucus degradation by pepsin I: Implications in peptic ulceration. Gut 1986;27:243–248.
    External Resources
  53. Berstad A, Holm HA, Kittang E: Experience with antipeptic agents. Scand J Gastroenterol 1979;(suppl 55)14:121–123.
  54. Becker R, Scholtholt J, Speth O, Scholkens B: Regional blood flow and haemodynamics in anaesthetised dogs during somatostatin-secretin infusion (abstract). Arch Pharmacol 1981;316(suppl):R46.
  55. McCormick PA, Jenkins SA, McIntyre N, Burroughs AK: Why portal hypertensive varices bleed and bleed: A hypothesis. Gut 1995;36:100–102.
    External Resources
  56. Gabryelewicz A, Prokopowicz J, Hnidec O, Wolosowicz N: The effect of chronic administration of SST on the hemostatic system in the dog. Prezeg Lek 1981;387:719–721.
  57. Szabo S, Usadel KH: Cytoprotection-organoprotection by somatostatin: Gastric and hepatic lesions. Experientia 1982;38:254–256.
    External Resources
  58. Usadel KH, Kessler H, Rohr G, Kusterer K, Palitzsch KD, Schwedes U: Cytoprotective properties of somatostatin. Klin Wochenschr 1986;64 (suppl 7):59–63.
  59. Greco AV, Bianco A, Altomonte L, D’Acquarica L, Ghirlanda G: Effect of somatostatin on lower esophageal sphincter (les) pressure and serum gastrin in normal and achalasic subjects. Horm Metab Res 1982;14:26–28.
    External Resources
  60. Caldwell MTP, Marks P, Byrne PJ, Walsh TN, Hennessy TPJ: Hypotension induced by haemorrhage impairs lower oesophageal sphincter function. Br J Surg 1994;81:1517–1519.
    External Resources
  61. Straathoff JW, Tieleman S, Lamers CBHW, Masclee AAM: Somatostatin prevents meal induced alterations in lower esophageal sphincter function. Gut 1996;39(suppl 3):1039.
  62. Whitehouse I, Beglinger C, Fried M, Gyr K: The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 on pentagastrin-stimulated gastric acid secretion: A comparative study in man. Hepatogastroenterologica 1984;31:227–229.
  63. Whitehouse I, Beglinger C, Ruettimann C, Gyr K: Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue. Gut 1986;27:141–146.
    External Resources
  64. Olson JA, Loud FB, Christianssen J: Inhibition of meal stimulated gastric acid secretion by the octapeptide somatostatin analogue SMS 201-995. Gut 1987;28:464–467.
    External Resources
  65. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I: Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal pancreatic and biliary function and hormone release in normal man. Digestion 1987;36:108–124.
    External Resources
  66. Konturek SJ, Cieszkowski JB, Konturek J, Bielanski W, Schally AV: Effects of cyclic hexapeptide analogue of somatostatin on pancreatic secretion in dogs. Proc Soc Exp Biol Med 1985;178:68–72.
    External Resources
  67. Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 1989;157:459–462.
    External Resources
  68. Kohler E, Beglinger C, Dettwiler S, Whitehouse I, Gyr K: Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986;1:154–159.
    External Resources
  69. Baxter JN, Jenkins SA, Ellenbogen S, Roberts N: The effects of a somatostatin analogue SMS 201-995 on pancreatic secretion in the pig and man. Surg Res Commun 1988;4:215–228.
  70. Fuessl HS, Carolan G, Williams G, Bloom FR: Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth to caecum transit time in man. Digestion 1987;36:101–107.
    External Resources
  71. Dueno MI, Bai JC, Santangelo WC, Krejs GJ: Effect of somatostatin analogue on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987;32:1092–1096.
    External Resources
  72. Moller N, Petrany C, Cassidy D, Sheldon WL, Johnston DG, Laker MF: Effects of the somatostatin analog SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrate in normal man. Clin Sci 1988;75:345–350.
    External Resources
  73. Richards WO, Geer R, O’Dorisio TM, et al: Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 1990;49:483–487.
    External Resources
  74. Londong W, Angerer M, Kutz K, Landgraf R, Londong V: Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989;96:713–722.
    External Resources
  75. Hollenberg MD: Control of receptor function by homologous and heterologous ligands; in Poste C, Crooke ST (eds): Mechanisms of Receptor Regulation. New York, Plenum, 1985, pp 295–322.
  76. Somerville KW, Davies JG, Hawkey CJ, Henry DA, Hine KR, Langman MJS: Somatostatin in treatment of haematemesis and melaena. Lancet 1985;i:130–132.
  77. Panés J, Piqué JM, Bordas JM, et al: Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology 1994;19:55–60.
    External Resources
  78. Wagner PK, Rothmund M, Grönniger J: Sekretin versus Somatostatin bei akuter Blutung aus gastroduodenalen Ulcera und Erosionen, eine randomisierte Studie. (Secretin and somatostatin in treatment of acute upper gastrointestinal haemorrhage: A randomised trial). Klin Wochenschr 1983;61:285–289.
    External Resources
  79. Galmiche JP, Cassigneul J, Faivre J, et al: Somatostatin in peptic ulcer bleeding – results of a double-blind controlled trial. Int J Clin Pharm Res 1983;III:379–387.
  80. Basso N, Bagarani M, Bracci F, et al: Ranitidine and somatostatin. Their effects on bleeding from the upper gastrointestinal tract. Arch Surg 1986;121:833–835.
    External Resources
  81. Saperas E, Piqué JM, Pérez-Ayuso R, et al: Somatostatin compared with cimetidine in the treatment of bleeding peptic ulcer without visible vessel. Aliment Pharmacol Ther 1988;2:153–159.
    External Resources
  82. Kayasseh L, Keller U, Gyr K, Stalder GA: Somatostatin and cimetidine in peptic-ulcer haemorrhage. Lancet 1980;i:844–846.
  83. Coraggio F, Scarpato P, Spina M, Lombardi S: Somatostatin and ranitidine in the control of iatrogenic haemorrhage of the upper gastrointestinal tract. Br Med J 1984;289:224.
  84. Magnusson I, Ihre T, Johansson C, Seligson U, Törngren S, Uvnäs-Moberg K: Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage. Gut 1985;26:221–226.
    External Resources
  85. Antonioli A, Gandolfo M, Rigo GP, et al: Somatostatin and cimetidine in the control of acute upper gastrointestinal bleeding: A controlled multicenter study. Hepato-gastroenterology 1986;33:71–74.
  86. Torres AJ, Landa I, Hernández F, et al: Somatostatin in the treatment of severe upper gastrointestinal bleeding: A multicentre controlled trial. Br J Surg 1986;73:786–789.
    External Resources
  87. Lambropoulos LG, Greca A, Bakaris T, Flevaris CP: Somatostatin effectiveness in serious upper gastrointestinal hemorrhage. Gut 1996;39(suppl 3):A204.
  88. Bosch J, D’Amico G, Luca A, Garica-Pagan JC, Feu F, Escorsell A: Drug therapy for variceal hamorrhage; in Bosch J, Groszmann RJ (eds): Portal Hypertension. Pathophysiology and Treatment. Cambridge, Blackwell, 1994, pp 108–123.
  89. Jenkins SA: Emerging Differences in the Therapeutic Efficacy of Somatostatin and Octreotide in Gastroenterology and Surgery. Hong Kong, MediMedia Asia Publication, 1996.
  90. D’Amico G, Pagliaro L, Bosch J: The treatment of hypertension: A meta-analytic review. Hepatology 1995;22:332–354.
    External Resources
  91. Coraggio F, Catalano A, Masetto O, Moles DA, Rotondano G: The octreotide in the conservative treatment of upper digestive haemorrhages due to peptic lesions. Hepato-Gastroenterol 1990;(suppl II)37:A6.
  92. Coraggio F, Bertini G, Catalano A, Scarpato P, Gualdieri L: Clinical, controlled trial of somatostatin with ranitidine and placebo in the control of peptic haemorrhage of the upper gastrointestinal tract. Digestion 1989;43:190–195.
    External Resources
  93. Coraggio F, Rotondano G: Somatostatin in acute upper gastrointestinal bleeding due to peptic lesions. Retrospective review 1988–1993 (honorary lecture). Proc 2nd National Congress of Emergency Medicine. Napoli, Casa Editrice l’Antologia, 1995.
  94. Tulassay Z, Gupta R, Papp J, Bodnár A: Somatostatin versus cimetidine in the treatment of actively bleeding duodenal ulcer: A prospective, randomised, controlled trial. Am J Gastroenterol 1989;84:6–9.
    External Resources
  95. Coraggio F, Rotondano G, Balzanelli MG, Catalano A, Clemente F, Moccia F: Somatostatin prevents recurrent bleeding after endoscopic hemostasis of peptic ulcer haemorrhage: A preliminary report. Eur J Gastroenterol Hepatol 1997;submitted.
  96. Christensen E, Fauerholdt L, Schlichting P, Juhl E, Poulsen H, Tygstrap N: Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisolone. Gastroenterology 1981;81:944–952.
    External Resources
  97. Lin HJ, Perng CL, Wang K, Lee CH, Lee SD: Octreotide for arrest of peptic ulcer haemorrhage: A prospective, randomized controlled trial. Hepatogastroenterology 1995;42:856–860.
    External Resources
  98. Lin HJ, Wang K, Perng CL, Chua RT, Lee CH, Lee SD: Octreotide and heater probe thermocoagulation for arrest of peptic ulcer hemorrhage: A prospective, randomised, controlled trial. J Clin Gastroenterol 1995;21:95–98.
    External Resources
  99. Burroughs AK, Jenkins SA: Management strategies in bleeding oesophageal varices. Drugs 1992;44(suppl 2):1–72.
  100. Graham DY, Smith JL: The course of patients after variceal haemorrhage. Gastroenterology 1981;80:800–809.
    External Resources
  101. Pagliaro L, Burroughs AK, Sorenson TA, et al: Therapeutic controversies and randomised controlled trials: Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989;2:71–84.
  102. Lin HJ, Wang K, Perng CL, Lee FY, Lee CH and Lee SD: Natural history of bleeding peptic ulcers with a tightly adherent blood clot: A prospective observation. Gastrointest Endosc 1996;43:470–473.
    External Resources
  103. McLeod IA, Mills PR: Factors identifying the probability of further haemorrhage after acute upper gastrointestinal haemorrhage. Br J Surg 1982;69:256–258.
    External Resources
  104. Perng CL, Lin HJ, Chen CJ, Lee FY, Lee SD, Lee CH: Characteristics of patients with bleeding peptic ulcer requiring emergency endoscopy and aggressive treatment. Am J Gastroenterol 1994;89:1811–1814.
    External Resources
  105. Imperiale TF, Birgisson S: Somatostatin or octreotide compared with H2-antagonists and placebo in the management of acute non-variceal upper gastrointestinal haemorrhage: A meta-analysis. Ann Intern Med 1997;127:1062–1071.
    External Resources
  106. Barer D, Ogilbie A, Henry D, et al: Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med 1983;308:1571–1575.
    External Resources
  107. Zuckerman G, Welch R, Douglas A, et al: Controlled trial of medical therapy for active upper gastrointestinal bleeding and prevention of re-bleeding. Am J Med 1984;76:361–366.
    External Resources
  108. Collins R, Langman M: Treatment with histamine H2 antagonists in acute upper gastrointestinal haemorrhage: Implications of randomized trials. N Engl J Med 1985;313:660–666.
    External Resources
  109. Saltzman JR, Zawacki JK: Therapy for bleeding peptic ulcers. N Engl J Med 1997;15:1091.
  110. Daneshmend TK, Hawkey CJ, Langman MJS, Longan RF, Long RG, Walt RP: Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomised double-blind controlled study. Br Med J 1992;304:143–147.
  111. Hasselgren G, Lind T, Lundell L, et al: Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Scand J Gastroenterol 1997;32:328–333.
    External Resources
  112. Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al: Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Scand J Gastroenterol 1997;32:320–327.
    External Resources
  113. Khuroo MS, Yattoo GN, Javid G, et al: A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336:1054–1058.
    External Resources
  114. Berstad A: Does profound acid inhibition improve hemostasis in peptic ulcer bleeding? Scand J Gastroenterol 1997;32:396–398.
    External Resources

Article / Publication Details

Published online: November 17, 1999
Issue release date: November 1999

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1999, Vol.60, Suppl. 3

November 1999

Article

Recommend This
TOP